Dianthus Therapeutics (DNTH) Retained Earnings (2017 - 2025)
Historic Retained Earnings for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to -$272.3 million.
- Dianthus Therapeutics' Retained Earnings fell 8650.68% to -$272.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$272.3 million, marking a year-over-year decrease of 8650.68%. This contributed to the annual value of -$174.4 million for FY2024, which is 9501.92% down from last year.
- Latest data reveals that Dianthus Therapeutics reported Retained Earnings of -$272.3 million as of Q3 2025, which was down 8650.68% from -$235.5 million recorded in Q2 2025.
- In the past 5 years, Dianthus Therapeutics' Retained Earnings ranged from a high of -$45.9 million in Q4 2022 and a low of -$434.5 million during Q2 2023
- Over the past 4 years, Dianthus Therapeutics' median Retained Earnings value was -$174.4 million (recorded in 2024), while the average stood at -$208.6 million.
- As far as peak fluctuations go, Dianthus Therapeutics' Retained Earnings soared by 7606.68% in 2024, and later tumbled by 9758.04% in 2025.
- Dianthus Therapeutics' Retained Earnings (Quarter) stood at -$45.9 million in 2022, then plummeted by 94.96% to -$89.4 million in 2023, then crashed by 95.02% to -$174.4 million in 2024, then crashed by 56.14% to -$272.3 million in 2025.
- Its Retained Earnings was -$272.3 million in Q3 2025, compared to -$235.5 million in Q2 2025 and -$203.9 million in Q1 2025.